Scarica l'app Stockscreener
3.17
1.86%
-0.06
Dopo l'orario di chiusura:
3.18
0.01
+0.32%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABCL Giù?
Forum
Previsione
Abcellera Biologics Inc Borsa (ABCL) Ultime notizie
AbCellera Biologics (NASDAQ:ABCL) Shares Down 4%Here's Why - MarketBeat
AbbVie, AbCellera expand collaboration into T-cell engagers - MSN
ABCL (AbCellera Biologics) Shares Outstanding (EOP) : 295.16 Mil (As of Sep. 2024) - GuruFocus.com
AbCellera Biologics (NASDAQ:ABCL) Shares Up 18.8%Here's What Happened - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 18.8%Here's What Happened - MarketBeat
Abcellera Biologics, other AI health stocks gain as Ellison touts AI's promise - MSN
Abcellera Biologics Inc (ABCL-Q) QuotePress Release - The Globe and Mail
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025 - BioSpace
AbCellera Biologics Inc. (NASDAQ:ABCL) most popular amongst individual investors who own 36% of the shares, institutions hold 29% - Yahoo Finance
AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 10.5%Time to Buy? - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Stock Price Down 6.7%What's Next? - MarketBeat
AbCellera Biologics Inc. (ABCL): A Bull Case Theory - Insider Monkey
AbCellera Biologics (NASDAQ:ABCL) Trading Up 10.5%What's Next? - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Shares Down 6.7%Here's Why - MarketBeat
Geode Capital Management LLC Sells 201,213 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World
Geode Capital Management LLC Has $295,000 Stock Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology - sharewise
AbCellera and AbbVie expand oncology collaboration - Investing.com
AbCellera and AbbVie expand oncology collaboration By Investing.com - Investing.com South Africa
KeyCorp Issues Pessimistic Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock Price - Defense World
AbCellera Biologics (NASDAQ:ABCL) Price Target Cut to $4.00 by Analysts at KeyCorp - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Stock Price Down 7.9%What's Next? - MarketBeat
Is AbCellera Biologics Inc. (ABCL) Among the Best Canadian Penny Stocks to Buy According to Analysts? - Insider Monkey
12 Best Canadian Penny Stocks to Buy According to Analysts - Insider Monkey
AbCellera Biologics (NASDAQ:ABCL) Trading Up 7.2%Time to Buy? - MarketBeat
Stifel Financial Corp Has $195,000 Stock Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World
AbCellera Biologics (NASDAQ:ABCL) Stock Price Down 6%What's Next? - MarketBeat
Sanctuary Advisors LLC Sells 10,808 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World
US Penny Stocks To Watch In December 2024 - Simply Wall St
AbCellera Biologics: Still A Concept Stock (NASDAQ:ABCL) - Seeking Alpha
Is AbCellera Biologics (NASDAQ:ABCL) In A Good Position To Invest In Growth? - Yahoo Finance
AbCellera Biologics (NASDAQ:ABCL) Trading Up 3.3%Should You Buy? - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Shares Gap UpHere's What Happened - MarketBeat
Walleye Capital LLC Makes New $668,000 Investment in AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat
AbCellera Biologics (FRA:8QQ) Price-to-Owner-Earnings : (As of Dec. 07, 2024) - GuruFocus.com
PDT Partners LLC Sells 173,884 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat
AbCellera's SWOT analysis: biotech firm's stock faces pivotal year By Investing.com - Investing.com Canada
AbCellera's SWOT analysis: biotech firm's stock faces pivotal year - Investing.com India
AbCellera Biologics (FRA:8QQ) Degree of Operating Leverage : -1.44 (As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Net Issuance of Debt : $3.95 Mil (TTM As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Pre-Tax Income : $-202.17 Mil (TTM As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Capex-to-Revenue : 2.85 (As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Buildings And Improvements : $66.92 Mil (As of Sep. 2024) - GuruFocus.com
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):